CareDx, Inc (CDNA)
$
19.19
-0.30 (-1.56%)
Key metrics
Financial statements
Free cash flow per share
0.7815
Market cap
995.8 Million
Price to sales ratio
2.7815
Debt to equity
0.0682
Current ratio
3.0318
Income quality
0.7004
Average inventory
28.1 Million
ROE
0.1741
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
CareDx, Inc. is dedicated to discovering, developing, and commercializing diagnostic solutions tailored for transplant patients and their caregivers globally. The company operates several innovative products, such as AlloSure Kidney, which utilizes donor-derived cell-free DNA (dd-cfDNA) for kidney transplant patients, and AlloMap Heart, a gene expression solution for heart transplant recipients. Additionally, it provides AlloSure Heart and AlloSure Lung, both dd-cfDNA solutions for heart and lung transplant patients, respectively. CareDx also introduces TruSight HLA, which is a next generation sequencing (NGS) based high-resolution typing solution, alongside Olerup SSP for typing human leukocyte antigen (HLA) alleles through sequence-specific primer technology. Other offerings include QTYPE for precise HLA typing, Ottr for transplant patient management, AlloSeq Tx for high-resolution HLA typing, AlloSeq cfDNA for blood surveillance of dd-cfDNA, AlloSeq HCT for chimerism testing in stem cell transplant recipients, and XynQAPI for transplant quality tracking. The company also offers AlloCare, a mobile app aimed at providing patient-centric resources for transplant recipients. CareDx markets its products directly to customers and utilizes third-party distributors and sub-distributors. The company has secured a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products, and with Cibiltech SAS to commercialize iBox, a predictive analysis software for post-transplantation kidney allograft loss. The company incurred an income tax expense of $310,000.00 indicating its tax obligations. It recorded a notable revenue of $333,785,000.00 showcasing its steady growth. Additionally, CareDx reported depreciation and amortization expenses of $19,757,000.00 reflecting the wear and tear of its assets, while the net total of other income and expenses is $12,094,000.00 reflecting non-core financial activities. Finally, the company incurred an interest expense of $0.00 reflecting its debt servicing obligations. The stock of CareDx is affordable at $14.59 making it a suitable option for budget-conscious investors. The stock has an average trading volume of 1,070,708.00 indicating moderate liquidity, which could attract interest from various investors. With a market capitalization of $987,029,667.00 the company is classified as a small-cap player, offering unique investment opportunities within the market. CareDx is recognized as a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative products and solutions. Furthermore, it belongs to the Healthcare sector, where it drives innovation and growth, establishing its pivotal role in the advancement of transplant diagnostics and patient care.
Is CareDx, Inc (CDNA) a good investment?
Investing in CareDx, Inc (CDNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is CareDx, Inc (CDNA)'s stock forecast?
Analysts predict CareDx, Inc stock to fluctuate between $10.96 (low) and $25.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is CareDx, Inc's market capitalization?
As of 2025-12-18, CareDx, Inc's market cap is $987,029,667, based on 51,434,584 outstanding shares.
How does CareDx, Inc compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., CareDx, Inc has a Lower Market-Cap, indicating a difference in performance.
How can I buy CareDx, Inc (CDNA) stock?
To buy CareDx, Inc (CDNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CDNA. Place an order (Market, Limit, etc.).
What is the best time to invest in CareDx, Inc?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did CareDx, Inc perform in the last earnings report?
Revenue: $333,785,000 | EPS: $1 | Growth: -128.25%.
Where can I find CareDx, Inc's investor relations reports?
Visit https://www.caredx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for CareDx, Inc?
You can explore historical data from here
What is the all-time high and low for CareDx, Inc stock?
All-time high: $84.94 (2021-08-06) | All-time low: $4.80 (2023-10-27).
What are the key trends affecting CareDx, Inc stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAYSEN Case No. 3:25-cv-02036-TLT STEVENSON, and CHRISTIAN JACOBSEN, (Shareholder Derivative Action) Derivatively on Behalf of CareDx, Inc., SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE ACTION Plaintiffs, v. GEORGE BICKERSTAFF,.
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 28% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
businesswire.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the third manuscript from Surveillance HeartCare Outcomes Registry (SHORE) in the Journal of Heart and Lung Transplantation (JHLT). The analysis, titled “Multimodal Molecular Testing Prov.
seekingalpha.com
CareDx, Inc ( CDNA ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Tina Jacobsen John Hanna - President, CEO & Director Nathan Smith - Chief Financial Officer Keith Kennedy - Chief Operating Officer Conference Call Participants Margarate Boeye - William Blair & Company L.L.C., Research Division Vidyun Bais - BTIG, LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Harrison Parsons - Stephens Inc., Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Operator Hello, and thank you for standing by.
zacks.com
While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
CareDx (CDNA) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.14 per share a year ago.
businesswire.com
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, inclu.
benzinga.com
CareDx, Inc. CDNA faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company's expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.
seekingalpha.com
CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.
See all news
